Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Tuesday luly 9. -, - - - -, I IF - - 1.11

TuPeB4474 Switch to a simple boosted double protease
inhibitor regimen of lopinavir/r and saquinavir
without reverse transcriptase inhibitors after
multiple therapy failures
S Staszewski, B Dauer, C Stephan, P Gute,
S Klauke, M Sturmer (Germany)
TuPeB4475 Predictors and consequences of switching highly
active antiretroviral therapy regimens
L P Jacobson, X Li, J B Margolick, CS Conover,
S A Riddler, R Detels (United States)
TuPeB4476 The efficacy of antiretroviral therapy (ART) in HIVinfected adults who have failed at least one PIbased regimen: a meta-analysis
E Losina, A C Pollock, R Islam, P E Sax,
K A Freedberg, R P Walensky (United States)
TuPeB4477 Genotype vs virtual phenotype for the management
of HAART in highly pre-treated patients
F Maggiolo, A Callegaro, G P Gregis, G P Quinzan,
C Arici, D Ripamonti, C Passerini-Tosi, A Goglio,
F Suter (Italy)
TuPeB4478 Phenotypic resistance and virologic responses to
indinavir (IDV) 8oo00 mg-ritonavir (RTV) 200 mg
bid-based salvage regimens in patients with prior
protease inhibitor (PI) failures
RE Campo, J Szumiloski, P N Lichtenberger,
N Miller, N S Hellmann, H King, M P Bates,
B P Unger, D J Holder, J H Condra (United States)
TuPeB4479 Phenotypic and genotypic profiles predict week
Tuesday 24 response to an abacavir-containing salvage
regimen
D Mildvan S Nowling, FAhmed, A Marshak
(United States)
TuPeB448o Patient survey on injection of T-2o: ease of use
and impact on activities
J Green M P Salgo, J Delehanty (United States)
TuPeB4481 Virologic and immunologic responses of 292 ARVexperienced patients enrolled in the
lopinavir/ritonavir expanded access program in
Toronto, Canada
M Loutfy, C Thompson, M Trpeski, C Kovacs,
A Rachlis, J Goodhew, G Rubin, K Gough,
S Walmsley (Canada)
TuPeB4482 Efficacy of the combination of Amprenavir,
Ritonavir and Efavirenz in multiply pretreated
HIV-infected patients: two years follow up
K Rdmer B Salzberger, G Fdtkenheuer (Germany)
TuPeB4483 Analysis of delavirdine use in a cohort of hiv
positive haart experienced patients
KS Greenberg (United States)
TuPeB4484 Retrospective observational study of combination
delavirdine and lopinavir/ritonavir as part of
salvage therapy in highly treatment-experienced
patients
R M Novak K Greenberg, M Diaz-Linares,
M Schutz, W C Woodward, I R Kostman,
P Benson, D S Rubin, S Segal-Maurer
(United States)
TuPeB4485 Lopinavir/r Containing-Regimens in Heavily Pretreated HIV-Infected Patients. Brazilian Experience
M S Oliveira, M I B Lopes, 0 H M Leite,
B G Grinsztejn, ] V R Madruga, I Caracciolo,
S Queiroz, I H Pilotto, FSantana, A Schubach,
M Barros, M Galhardo, D E Uip (Brazil)
TuPeB4486 Delavirdine as a highly active component of a
salvage regimen: safety, efficacy & durability
Eron, P Bellman (United States)
TuPeB4487 Impact of multi drug rescue therapy of resistant

HIV overextended follow up
S Schneider R L Sheneberger, R Cordova
(United States)

TuPeB4488 Individualizing salvage therapy: the ihibitory
quotient as a predictor of virological response
J L Casado1, A Moreno', K Hertogs2, R Sabido',
P Martf-Belda, A Antela', F Dronda, MJ PdrezElfas', S Moreno' (Spain; 2Belgium)
TuPeB4489 Efavirenz does not affect Amprenavir exposure
when co-administered with Ritonavir in HIV-1+
subjects
R G Hewitt, D Cloen, T Olatinwo (United States)
TuPeB449o Virological response at 48 weeks with
Lopinavir/R based therapy in patients failing
more than 1 HAART regimen
P Patterson, C Zala, P Coll, S Kaufman, I Zapiola,
A Gun, H Perez, P Cahn (Argentina)
TuPeB4491 Relationship between plasmatic lipids and body
fat composition measured by computed
tomography in HIV-infected patients
S Padilla, JA Gallego, FArdoy, M Masia,
J M Ramos, C Escolano, A Navarro, A Martin
Hidalgo, F Perez-Paya, F Gutierrez (Spain)
TuPeB4492 Virological response and safety at 48 weeks of
double boosted protease inhibitors with
Lopinavir/R plus either Saquinavir or Amprenavir
in heavily pretreated HIV infected patients
C Zala, P Patterson, P Coll, M B Bouzas,
S Kaufman, A Gun, H Perez, P Cahn (Argentina)
TuPeB4493 Virological response at 48 weeks with Lopinavir/r
based therapy in patients failing more than 1
HAART regimen
P Patterson C Zala, P Coll, S Kaufman, I Zapiola,
A Gun, H Pdrez, P Cahn (Argentina)
TuPeB4494 Protease inhibitor drug use and adverse
cardiovascular events in ambulatory HIV-infected
patients
S D Holmberg, A C Moorman, T C Tong, D JWard,
K C Wood, A E Greenberg, R S ]anssen
(United States)
TuPeB4495 Tunnel carpal syndrome in HIV patients
J A Arranz-Caso, 0 Asensio, R Rojas, E Casas,
J De Miguel, J Sanz (Spain)
TuPeB4496 Frequency and clinical significance of pancreatic
abnormalities during HIV disease: to treat or not
to treat?
R Manfredi, L Calza, F Chiodo (Italy)
TuPeB4497 Urinary 8-Hydroxy-2'-Deoxyguanosine, a
metabolite of oxidized DNA, is not elevated in HIV
patients on combination antiretroviral therapy
S Paul, M B Bogdanov, L Metakis, W R Matson,
J Jacobs, M F Beal (United States)
TuPeB4498 Use of fibrates and statins in the treatment of
hyperlipidemia in HIV-infected patients receiving
HAART
L Calza, R Manfredi, F Chiodo (Italy)
TuPeB4499 Differences in hematological complications in the
selection of thymidine analog regimen therapy
trials (START I and START II)
A Pavia, I S Olson, I Mauney, B Wills
(United States)
TuPeB45oo Assessment of Lymphocyte Mitochondrial
Biomarkers (LBMs) in HIV Infected Subjects with
Extensive Exposure to Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) and in Matched
HIV-Negative Controls
K Henry A Erice, H Balfour, I Webb, M Schmeling,
I Berthiaume, K Wallace (United States)
TuPeB45ol Lactase activity and cell survival in intestinal cell
lines treated with protease inhibitors

A Andrade C Flexner, S Kim, C Sears
(United States)

96 Final Program